NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SGHT

Sight Sciences Inc

Jul 08 • 04:00PM ET

3.55

Dollar change +0.07
Percentage change 2.01	%

Healthcare • Medical Devices • USA • NASD

Peers: ALGN CNMD INSP IRTC MMSI CUTR ARAY SMLR STXS RCEL

| Held by: VTI IWM VXF IWO VTWO SCHA IWC SMLF AVSC DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.98	Insider Own	47.79%	Shs Outstand	51.38M	Perf Week	-14.16%
Market Cap	183.28M	Forward P/E	-	EPS next Y	-0.90	Insider Trans	0.63%	Shs Float	26.99M	Perf Month	-15.60%
Enterprise Value	114.97M	PEG	-	EPS next Q	-0.26	Inst Own	30.92%	Short Float	4.25%	Perf Quarter	54.13%
Income	-49.40M	P/S	2.35	EPS this Y	-3.28%	Inst Trans	-10.39%	Short Ratio	6.48	Perf Half Y	-0.98%
Sales	78.11M	P/B	2.35	EPS next Y	15.35%	ROA	-34.63%	Short Interest	1.15M	Perf YTD	-2.61%
Book/sh	1.51	P/C	1.69	EPS next 5Y	11.93%	ROE	-52.87%	52W High	8.45 -58.05%	Perf Year	-42.73%
Cash/sh	2.10	P/FCF	-	EPS past 3/5Y	8.14% -13.18%	ROIC	-42.02%	52W Low	2.03 74.63%	Perf 3Y	-60.57%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	17.72% 27.89%	Gross Margin	85.66%	Volatility	9.96% 6.25%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.47	EPS Y/Y TTM	12.79%	Oper. Margin	-63.59%	ATR (14)	0.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.99	Sales Y/Y TTM	-4.16%	Profit Margin	-63.24%	RSI (14)	39.67	Recom	2.43
Dividend Gr. 3/5Y	- -	Current Ratio	10.47	EPS Q/Q	16.03%	SMA20	-13.84%	Beta	2.47	Target Price	3.77
Payout	-	Debt/Eq	0.52	Sales Q/Q	-9.12%	SMA50	-3.45%	Rel Volume	0.94	Prev Close	3.47
Employees	216	LT Debt/Eq	0.51	Earnings	May 08 AMC	SMA200	-4.94%	Avg Volume	176.90K	Price	3.55
IPO	Jul 15, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.92% 6.03%	Trades		Volume	166,373	Change	2.01%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	UBS	Buy	$5.50
Nov-04-24	Downgrade	Lake Street	Buy → Hold	$10 → $5
Aug-21-24	Initiated	Lake Street	Buy	$10
Sep-12-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-12-23	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $5.50
Sep-12-23	Downgrade	BofA Securities	Neutral → Underperform	$10 → $4.50
Aug-24-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$12 → $8.40
Jul-10-23	Downgrade	Citigroup	Buy → Neutral	$15 → $9
Jan-06-23	Upgrade	Stifel	Hold → Buy	$10 → $15
Oct-04-22	Initiated	Needham	Hold
Jul-26-22	Initiated	Stifel	Hold	$10
Feb-03-22	Initiated	William Blair	Outperform
Jan-07-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$36 → $27

Show Previous Ratings

May-14-25 04:05PM	Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th (GlobeNewswire)
May-09-25 03:41AM	Sight Sciences Inc (SGHT) Q1 2025 Earnings Call Highlights: Navigating Market Challenges and ... (GuruFocus.com)
May-08-25 06:30PM	Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +5.94%
05:45PM	Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance (GlobeNewswire)
11:25AM	Loading…
May-07-25 11:25AM	Sight Sciences Inc (SGHT) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-05-25 05:45PM	Artivion (AORT) Lags Q1 Earnings Estimates (Zacks)
Apr-24-25 04:05PM	Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-23-25 04:05PM	Sight Sciences Announces the Release of its Sustainability Report (GlobeNewswire) +7.36%
Apr-22-25 04:05PM	Sight Sciences Appoints Gary Burbach to its Board of Directors (GlobeNewswire) +8.33%
Apr-21-25 04:05PM	Sight Sciences to Debut OMNI Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio (GlobeNewswire)
Mar-25-25 04:05PM	Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th (GlobeNewswire) -12.38%
Mar-06-25 12:09PM	Q4 2024 Sight Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Sight Sciences Inc (SGHT) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Challenges (GuruFocus.com)
Mar-05-25 06:00PM	Compared to Estimates, Sight Sciences (SGHT) Q4 Earnings: A Look at Key Metrics (Zacks)
05:20PM	Loading…
05:20PM	Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance (GlobeNewswire)
Mar-04-25 07:25AM	Earnings To Watch: Sight Sciences Inc (SGHT) Reports Q4 2024 Result (GuruFocus.com)
Feb-26-25 10:00AM	Will Sight Sciences, Inc. (SGHT) Report Negative Earnings Next Week? What You Should Know (Zacks) +12.85%
Feb-24-25 04:05PM	Sight Sciences to Present Comprehensive Clinical Data on the OMNI Surgical System at the 2025 American Glaucoma Society Annual Meeting (GlobeNewswire)
Feb-19-25 04:05PM	Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025 (GlobeNewswire)
Feb-13-25 04:05PM	Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day (GlobeNewswire) +7.03%
Jan-14-25 08:00AM	Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights (GlobeNewswire)
Jan-07-25 04:05PM	Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma (GlobeNewswire)
Dec-19-24 04:05PM	Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare System for the Treatment of Meibomian Gland Disease ( MGD ) Showing Cost Savings Over Existing Reimbursed Treatment Options (GlobeNewswire) +6.25%
Dec-07-24 05:31AM	Sight Sciences initiated with a Buy at UBS (TipRanks)
Nov-19-24 04:05PM	Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 10:00AM	Inside a $400 billion bet on the brain-computer interface revolution (Yahoo Finance)
Nov-12-24 06:50AM	Sight Sciences price target lowered to $5 from $7 at Morgan Stanley (TipRanks) -7.84%
Nov-08-24 06:02AM	Sight Sciences Inc (SGHT) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) -9.62%
07:05PM	Loading…
Nov-07-24 07:05PM	Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -8.24%
04:05PM	Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance (GlobeNewswire)
04:04PM	Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations (GlobeNewswire)
Nov-06-24 07:43AM	Sight Sciences Inc (SGHT) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com) +8.28%
Oct-17-24 04:05PM	Sight Sciences to Report Third Quarter Financial Results on November 7, 2024 (GlobeNewswire)
Oct-14-24 04:05PM	Single TearCare Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial (GlobeNewswire) +7.67% -5.99%
Aug-21-24 09:36AM	AmEx downgraded, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly)
Aug-20-24 04:05PM	Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-02-24 11:30AM	Q2 2024 Sight Sciences Inc Earnings Call (Thomson Reuters StreetEvents) -14.96%
Aug-01-24 06:45PM	Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance (GlobeNewswire)
Jul-18-24 04:05PM	Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 (GlobeNewswire) -6.13%
Jun-10-24 04:05PM	Sight Sciences Announces the Release of its First Sustainability Report (GlobeNewswire)
May-28-24 04:05PM	Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis (GlobeNewswire) +7.54% +5.51%
08:30AM	Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI Across Mild, Moderate, and Advanced Glaucoma (GlobeNewswire)
May-07-24 04:05PM	Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference (GlobeNewswire)
May-06-24 10:02AM	Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 01:37PM	Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed (MT Newswires) +6.24%
01:04PM	Q1 2024 Sight Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
May-02-24 09:55PM	SGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:20PM	Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance (GlobeNewswire)
Apr-30-24 11:02AM	Sight Sciences awarded $34m in Alcon patent infringement case (Medical Device Network)
Apr-29-24 03:55PM	Sector Update: Health Care Stocks Edge Higher Late Afternoon (MT Newswires) +10.23%
01:59PM	Sector Update: Health Care Stocks Rise in Monday Afternoon Trading (MT Newswires)
11:21AM	Update: Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump (MT Newswires)
10:51AM	Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump (MT Newswires)
08:05AM	Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery (GlobeNewswire)
Apr-18-24 04:05PM	Sight Sciences to Report First Quarter Financial Results on May 2, 2024 (GlobeNewswire)
Apr-10-24 04:05PM	Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma (GlobeNewswire)
Apr-02-24 04:05PM	Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (GlobeNewswire)
Mar-26-24 04:05PM	Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference (GlobeNewswire)
Mar-08-24 02:53PM	Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2023 Earnings Call Transcript (Insider Monkey) +6.09%
09:16AM	Q4 2023 Sight Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 10:35PM	Sight Sciences Inc (SGHT) Navigates Challenges to Maintain Revenue Growth and Reduce Expenses (GuruFocus.com)
09:53PM	SGHT Stock Earnings: Sight Sciences Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:50PM	Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance (GlobeNewswire)
Feb-22-24 04:05PM	Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024 (GlobeNewswire)
Feb-21-24 10:25AM	Sight Sciences (SGHT) to Expand in Europe With New Launch (Zacks)
Feb-14-24 04:05PM	Sight Sciences Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting (GlobeNewswire)
Jan-23-24 04:05PM	Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital (GlobeNewswire) -9.68% -11.28%
Jan-14-24 05:25PM	Billionaire Steve Cohen Aggressively Bought These 5 Stocks Recently (Insider Monkey)
Jan-08-24 04:05PM	Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights (GlobeNewswire) +5.11%
Dec-28-23 09:15AM	Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors (GlobeNewswire) -5.63%
Dec-18-23 04:05PM	Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Disease (GlobeNewswire)
Dec-08-23 08:05AM	Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI Surgical System Technology (GlobeNewswire) +8.30%
Nov-13-23 03:40PM	5 Risky Stocks to Buy Immediately, According to AI (InvestorPlace)
Nov-12-23 09:40AM	Sight Sciences, Inc. (NASDAQ:SGHT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 04:05PM	Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023 (GlobeNewswire) +22.09%
Oct-26-23 05:30PM	Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -64.27% +16.28%
Oct-24-23 04:05PM	Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-19-23 04:05PM	Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023 (GlobeNewswire) -6.63%
Oct-12-23 04:05PM	Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting (GlobeNewswire)
Oct-03-23 08:30AM	Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR Using OMNI Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma (GlobeNewswire) +5.93%
Sep-12-23 09:53AM	CVS upgraded, RTX downgraded: Wall Street's top analyst calls (The Fly) -49.62%
02:55AM	4 big analyst cuts: RTX pelted with 2 downgrades on word of $3B hit (Investing.com)
Sep-11-23 04:06PM	Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023 and Updates Revenue Guidance for Full Year 2023 (GlobeNewswire) +6.03%
04:05PM	Sight Sciences Appoints Matt Link as Chief Commercial Officer (GlobeNewswire)
Aug-30-23 04:05PM	Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-03-23 06:35PM	Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +7.59%
04:05PM	Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023 (GlobeNewswire)
Jul-24-23 09:55AM	Wall Street Analysts Predict a 44.19% Upside in Sight Sciences, Inc. (SGHT): Here's What You Should Know (Zacks)
Jul-20-23 04:05PM	Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire) +16.06%
08:30AM	Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye (GlobeNewswire)
Jul-17-23 12:00PM	All You Need to Know About Sight Sciences, Inc. (SGHT) Rating Upgrade to Buy (Zacks) -6.03%
Jun-21-23 08:30AM	Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy) (GlobeNewswire)
Jun-09-23 04:05PM	Sight Sciences Announces Addition of New Director Catherine Mazzacco (GlobeNewswire)
May-23-23 08:30AM	Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology (GlobeNewswire)
May-09-23 09:55AM	How Much Upside is Left in Sight Sciences, Inc. (SGHT)? Wall Street Analysts Think 38.78% (Zacks)

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HAYDEN JEREMY B.	Chief Legal Officer	Jul 03 '25	Sale	4.17	9,160	38,234	266,321	Jul 07 09:32 PM
Bauerlein Alison	Chief Financial Officer	Jul 02 '25	Sale	4.10	19,260	78,927	617,468	Jul 07 09:27 PM
Badawi Paul	President and CEO	Jul 01 '25	Sale	4.15	23,637	98,141	5,986,943	Jul 07 09:27 PM
Badawi David	Chief Technology Officer	Jul 03 '25	Sale	4.17	5,679	23,704	1,831,025	Jul 07 09:25 PM
Link Matthew	Chief Commercial Officer	Jul 02 '25	Sale	4.10	4,889	20,035	832,293	Jul 07 09:24 PM
Badawi David	Officer	Jul 03 '25	Proposed Sale	4.17	5,679	23,705		Jul 03 03:13 PM
HAYDEN JEREMY B.	Officer	Jul 03 '25	Proposed Sale	4.17	9,160	38,236		Jul 03 03:05 PM
Link Matthew	Officer	Jul 02 '25	Proposed Sale	4.10	4,889	20,037		Jul 02 04:45 PM
Bauerlein Alison	Officer	Jul 02 '25	Proposed Sale	4.10	19,260	78,933		Jul 02 04:37 PM
Badawi Paul	Officer	Jul 01 '25	Proposed Sale	4.15	23,637	98,134		Jul 01 04:27 PM
Encrantz Staffan	Director	Jun 05 '25	Buy	4.24	40,951	173,796	1,319,112	Jun 06 09:10 PM
Encrantz Staffan	Director	Jun 06 '25	Buy	4.22	27,900	117,738	1,377,964	Jun 06 09:10 PM
Encrantz Staffan	Director	Jun 04 '25	Buy	4.17	21,674	90,424	1,278,161	Jun 06 09:10 PM
Encrantz Staffan	Director	May 30 '25	Buy	3.67	42,753	156,904	1,200,458	Jun 03 09:57 PM
Encrantz Staffan	Director	Jun 02 '25	Buy	3.88	30,799	119,439	1,231,257	Jun 03 09:57 PM
Encrantz Staffan	Director	Jun 03 '25	Buy	3.97	25,230	100,087	1,256,487	Jun 03 09:57 PM
Encrantz Staffan	Director	May 29 '25	Buy	3.59	60,128	215,739	1,157,705	May 29 09:31 PM
Encrantz Staffan	Director	May 27 '25	Buy	3.44	41,346	142,065	1,070,862	May 29 09:31 PM
Encrantz Staffan	Director	May 28 '25	Buy	3.52	26,715	93,930	1,097,577	May 29 09:31 PM
Bauerlein Alison	Chief Financial Officer	May 19 '25	Sale	3.48	13,066	45,430	636,728	May 21 08:38 PM
Bauerlein Alison	Officer	May 19 '25	Proposed Sale	3.48	13,066	45,430		May 19 03:52 PM
HAYDEN JEREMY B.	Chief Legal Officer	Apr 02 '25	Sale	2.31	9,395	21,693	275,481	Apr 03 09:57 PM
Badawi Paul	President and CEO	Apr 01 '25	Sale	2.30	24,174	55,673	6,010,580	Apr 03 09:56 PM
Link Matthew	Chief Commercial Officer	Apr 02 '25	Sale	2.31	5,042	11,642	830,551	Apr 03 09:56 PM
Badawi David	Chief Technology Officer	Apr 01 '25	Sale	2.30	5,980	13,772	1,836,704	Apr 03 09:55 PM
Bauerlein Alison	Chief Financial Officer	Apr 02 '25	Sale	2.31	19,397	44,788	649,794	Apr 03 09:54 PM
Link Matthew	Officer	Apr 02 '25	Proposed Sale	2.31	5,042	11,642		Apr 02 04:34 PM
HAYDEN JEREMY B.	Officer	Apr 02 '25	Proposed Sale	2.31	9,395	21,694		Apr 02 04:27 PM
Bauerlein Alison	Officer	Apr 02 '25	Proposed Sale	2.31	19,397	44,790		Apr 02 04:13 PM
Badawi Paul	Officer	Apr 01 '25	Proposed Sale	2.30	24,174	55,682		Apr 01 04:57 PM
Badawi David	Officer	Apr 01 '25	Proposed Sale	2.30	5,980	13,774		Apr 01 04:26 PM
Raheja Manohar K.	EVP, Research & Development	Mar 12 '25	Buy	2.73	10,000	27,250	145,000	Mar 13 09:51 PM
Raheja Manohar K.	EVP, Research & Development	Mar 13 '25	Buy	2.60	10,000	26,000	155,000	Mar 13 09:51 PM
Badawi David	Chief Technology Officer	Jan 17 '25	Sale	2.78	5,423	15,081	1,744,118	Jan 21 09:58 PM
Badawi Paul	President and CEO	Jan 16 '25	Sale	2.92	24,819	72,571	5,676,331	Jan 21 09:58 PM
HAYDEN JEREMY B.	Chief Legal Officer	Jan 17 '25	Sale	2.78	6,922	19,250	145,091	Jan 21 09:58 PM
HAYDEN JEREMY B.	Officer	Jan 17 '25	Proposed Sale	2.78	6,922	19,249		Jan 17 03:17 PM
Badawi David	Officer	Jan 17 '25	Proposed Sale	2.78	5,423	15,081		Jan 17 03:06 PM
Badawi Paul	Officer	Jan 16 '25	Proposed Sale	2.92	24,819	72,571		Jan 16 04:14 PM
HAYDEN JEREMY B.	Chief Legal Officer	Jan 08 '25	Sale	3.26	1,810	5,899	152,013	Jan 10 06:10 AM
Badawi David	Chief Technology Officer	Jan 08 '25	Sale	3.26	3,829	12,479	1,749,541	Jan 10 06:09 AM
Badawi David	Officer	Jan 08 '25	Proposed Sale	3.26	3,829	12,479		Jan 08 03:12 PM
HAYDEN JEREMY B.	Officer	Jan 08 '25	Proposed Sale	3.26	1,810	5,899		Jan 08 03:09 PM
Badawi David	Chief Technology Officer	Jan 03 '25	Sale	3.52	3,111	10,957	1,753,370	Jan 06 09:48 PM
HAYDEN JEREMY B.	Chief Legal Officer	Jan 03 '25	Sale	3.52	4,864	17,131	153,823	Jan 06 09:47 PM
Bauerlein Alison	Chief Financial Officer	Jan 03 '25	Sale	3.52	10,102	35,579	382,453	Jan 06 09:47 PM
Badawi Paul	President and CEO	Jan 02 '25	Sale	3.60	12,236	44,013	5,713,197	Jan 06 09:46 PM
HAYDEN JEREMY B.	Officer	Jan 03 '25	Proposed Sale	3.52	4,864	17,132		Jan 03 05:20 PM
Bauerlein Alison	Officer	Jan 03 '25	Proposed Sale	3.52	10,102	35,582		Jan 03 04:55 PM
Badawi David	Officer	Jan 03 '25	Proposed Sale	3.52	3,111	10,958		Jan 03 04:38 PM
Park Sam Boong	Former Officer	Jan 02 '25	Proposed Sale	3.60	3,323	11,953		Jan 02 03:45 PM
Badawi Paul	Officer	Jan 02 '25	Proposed Sale	3.60	12,236	44,014		Jan 02 03:43 PM
Raheja Manohar K.	EVP, Research & Development	Dec 06 '24	Buy	3.85	5,000	19,250	111,000	Dec 09 06:16 PM
Raheja Manohar K.	EVP, Research & Development	Dec 03 '24	Buy	3.89	3,376	13,133	106,000	Dec 05 08:18 PM
Raheja Manohar K.	EVP, Research & Development	Nov 29 '24	Buy	3.99	4,624	18,441	102,624	Dec 03 06:40 PM
Raheja Manohar K.	EVP, Research & Development	Nov 19 '24	Buy	3.70	2,000	7,400	98,000	Nov 21 09:18 PM
Encrantz Staffan	Director	Nov 21 '24	Buy	3.73	551,802	2,058,221	4,573,920	Nov 21 09:12 PM
Encrantz Staffan	Director	Nov 21 '24	Sale	3.73	551,802	2,058,221	632,456	Nov 21 09:12 PM
Link Matthew	Chief Commercial Officer	Oct 18 '24	Sale	5.98	20,487	122,451	685,381	Oct 21 09:46 PM
Link Matthew	Chief Commercial Officer	Oct 21 '24	Sale	5.61	21,831	122,450	663,550	Oct 21 09:46 PM
Link Matthew	Officer	Oct 21 '24	Proposed Sale	5.61	21,831	122,441		Oct 21 04:13 PM
Link Matthew	Chief Commercial Officer	Oct 17 '24	Sale	5.84	20,970	122,444	705,868	Oct 18 07:43 PM
Link Matthew	Chief Commercial Officer	Oct 16 '24	Sale	5.91	20,734	122,434	726,838	Oct 18 07:43 PM
Link Matthew	Officer	Oct 18 '24	Proposed Sale	5.98	20,487	122,441		Oct 18 03:44 PM
Link Matthew	Officer	Oct 17 '24	Proposed Sale	5.84	20,970	122,438		Oct 17 04:27 PM
Link Matthew	Officer	Oct 16 '24	Proposed Sale	5.91	20,734	122,440		Oct 16 04:01 PM
Badawi Paul	President and CEO	Oct 02 '24	Sale	5.99	12,727	76,184	5,725,433	Oct 03 09:57 PM
HAYDEN JEREMY B.	Chief Legal Officer	Oct 01 '24	Sale	6.08	4,878	29,658	158,687	Oct 03 09:57 PM
Badawi David	Chief Technology Officer	Oct 02 '24	Sale	5.99	3,167	18,958	1,756,481	Oct 03 09:53 PM
Bauerlein Alison	Chief Financial Officer	Oct 01 '24	Sale	6.08	10,130	61,590	392,555	Oct 03 09:53 PM
Park Sam Boong	Chief Operating Officer	Oct 01 '24	Sale	6.08	3,403	20,690	254,826	Oct 03 09:52 PM
Badawi Paul	Officer	Oct 02 '24	Proposed Sale	5.99	12,727	76,183		Oct 02 04:51 PM
Badawi David	Officer	Oct 02 '24	Proposed Sale	5.99	3,167	18,957		Oct 02 04:08 PM
Bauerlein Alison	Officer	Oct 01 '24	Proposed Sale	6.08	10,130	61,586		Oct 01 03:52 PM
Park Sam Boong	Officer	Oct 01 '24	Proposed Sale	6.08	3,403	20,689		Oct 01 03:40 PM
HAYDEN JEREMY B.	Officer	Oct 01 '24	Proposed Sale	6.08	4,878	29,656		Oct 01 03:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGHT

Sight Sciences Inc

Upgrade your FINVIZ experience